PALO ALTO, Calif.
Feb. 8, 2012
/PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate overview at the 14
& Investor Conference in
New York City
Tuesday, February 14
1:00 p.m. Eastern time
10:00 a.m. Pacific time
), in the Waldorf-Astoria Hotel's
. A live and archived webcast of the presentation will be available on the Telik website,
. The archived broadcast of the presentation can be accessed for 30 days following the presentation.
Telik, Inc. of
Palo Alto, CA
, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.
Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.
SOURCE Telik, Inc.